Endocrine Abstracts

JOINT1727

Introduction: Graves’disease is one of the usual indications of iratherapy in the Nuclear Medicine service whose main population followed to our service is young (20-40 years), addressed after failure of medical treatment (Carbimazol).

Objective: Highlight the effectiveness of Iratherapy as the most used therapeutic weapon in the young population.

Materiels and Methods: The files have been collected since 2021 and the information is transmitted on a sheet with the following criteria: Age/Number of cures/Recurrence/result (Hypothyroidism or euthyroidism) then statistical analysis of the sample.

Results: The majority of patients treated for Graves’ disease by iratherapy in our department, had a remission of their pathology with hypothyroidism as major side effect, rarely an euthyroidism. Recurrence after the first treatment is <10%, which required the administration of 2 to 3 additional treatments.

Discussion: The effectiveness of irathatherapy is no longer to be demonstrated in the literature and in current practice, and the results in our patients treated at our service confirm this trend. Resistance to iratherapy; requiring a 2nd, 3rd cure; is related to an increased volume of the thyroid gland at the time of administration of iodine 131; Patients with failed irathérapie are referred for surgery.

Conclusion: Iratherapy is an effective therapeutic weapon for Graves’ disease, to be preferred among the young and professionally active population with a very low recurrence rate.